Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 3/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | MGMT | P16455 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30716906 | 1.00 | SYK (0.54) | SYKHTR2CL3MBTL1HRH1MAOA | |
| SCHEMBL6500059 | 0.84 | HRH1 (0.51) | SYKL3MBTL1HRH1MAOAMAOB | |
| SCHEMBL6792817 | 0.83 | HRH1 (0.50) | SYKL3MBTL1HRH1MAOAMAOB | |
| SCHEMBL13661860 | 0.80 | SYK (0.54) | SYKHTR2CKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8123848 | 0.80 | KDM4E (0.39) | SYKHTR2CMEN1KMT2AKDM4E | |
| SCHEMBL11354880 | 0.80 | SMN1; SMN2 (0.51) | SYKHRH1PARP10KDM4EALDH1A1 | |
| SCHEMBL23406003 | 0.78 | GRM5 (0.48) | SYKHTR2CPARP10KDM4EALDH1A1 | |
| SCHEMBL29744012 | 0.78 | GRM5 (0.48) | SYKHTR2CPARP10KDM4EALDH1A1 | |
| SCHEMBL29417058 | 0.78 | ALDH1A1 (0.68) | HTR2CL3MBTL1PARP10KDM4EALDH1A1 | |
| SCHEMBL13052590 | 0.78 | ALDH1A1 (0.68) | HTR2CL3MBTL1PARP10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2108649-B1 | Novel indol carboxylic acid bispyridyl carboxamide derivatives as 5-HT2c receptor antagonists | KOREA RES INST CHEM TECH (KR) | 2013-04-24 | — | — | EP | claimed |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| US-20220339302-A1 | ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2022-10-27 | — | — | US | disclosed |
| CN-113382986-A | Tyrosine kinase inhibitor compositions, methods of making and methods of using the same | 黑钻治疗公司 | 2021-09-10 | — | — | CN | disclosed |
| EP-3856726-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | Black Diamond Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020068867-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-2108649-B1 | Novel indol carboxylic acid bispyridyl carboxamide derivatives as 5-HT2c receptor antagonists | KOREA RES INST CHEM TECH (KR) | 2013-04-24 | — | — | EP | disclosed |
| US-8324246-B2 | Indol carboxylic acid bispyridyl carboxamide derivatives, pharmaceutically acceptable salt thereof, preparation method and composition containing the same as an active ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-12-04 | — | — | US | disclosed |
| US-6670382-B2 | For inhibiting a synthase of 20-hydroxyeicosatetraenoic acid biosynthesized from arachidonic acid involved in constriction or dilation of microvessels in the kidneys and the cerebral blood vessels, or participates in cell proliferation | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-12-30 | — | — | US | disclosed |
| US-20030186979-A1 | Hydroxyformamidine derivatives and medicines containing the same | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2003-10-02 | — | — | US | disclosed |
| CN-1436173-A | Hydroxyformamidine derivatives and drugs containing the same | TAISHO PHARMACEUTICAL CO LTD (JP) | 2003-08-13 | — | — | CN | disclosed |
| EP-1291343-A1 | HYDROXYFORMAMIDINE DERIVATIVES AND MEDICINES CONTAINING THE SAME | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2003-03-12 | — | — | EP | disclosed |
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM P.L.C. | 2002-03-21 | — | — | US | disclosed |
| US-6313145-B1 | FOR THERAPY OF ANXIETY AND/OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-06 | — | — | US | disclosed |
| EP-0912556-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-10-04 | — | — | EP | disclosed |
| CN-1222152-A | Indoline derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-07-07 | — | — | CN | disclosed |
| EP-0912556-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997048700-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | ERBB2, ERBB3, EGFR | SYK 102/4885HTR2C 1443/4885L3MBTL1 2577/4885 |
| US-20030186979-A1 | Hydroxyformamidine derivatives and medicines containing the same | HTR3E, PGF, VEGFA | SYK 1972/4885HTR2C 23/4885L3MBTL1 4149/4885 |
| US-20220339302-A1 | ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, HSPBP1 | SYK 4645/4885HTR2C 1010/4885L3MBTL1 2794/4885 |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | SYK 102/4885HTR2C 1443/4885L3MBTL1 2577/4885 |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | SYK 102/4885HTR2C 1443/4885L3MBTL1 2577/4885 |
| US-20020035134-A1 | Indoline derivatives useful as 5-HT-2C receptor antagonists | HTR2C, HTR1A, HTR1D | SYK 1978/4885HTR2C 1/4885L3MBTL1 3194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.